Certification on Economic-Loss Bar and Athlete “Eligibility Injury” from Nonconsensual Ingestion of a Banned Substance

1. Introduction

This appeal arises from a high-profile anti-doping dispute involving Plaintiff-Appellant Issamade Asinga, a record-setting high school sprinter, and Defendant-Appellee The Gatorade Company (“Gatorade”). Asinga alleges that he ingested “Gatorade Recovery Gummies” that were contaminated with cardarine, a banned performance-enhancing drug, after relying on a purported “NSF Certified for Sport” logo indicating independent testing and freedom from banned substances.

According to the complaint, a positive test for trace cardarine triggered suspension and cascading professional and educational consequences: loss of eligibility to compete in elite events, loss of scholarship opportunities, stripped records, and lost endorsement prospects. The district court dismissed strict products liability, negligence, and negligent misrepresentation as barred by New York’s “economic loss doctrine,” reasoning that Asinga alleged only economic damages because the bodily change was not independently detectable absent laboratory testing and did not impair athletic performance.

The Second Circuit concluded that New York law is unsettled as to (i) whether tort claims may be barred as “duplicative” when contract/products-liability avenues are not viable, and (ii) whether an “eligibility-to-compete” impairment caused by nonconsensual ingestion constitutes a cognizable injury in tort. It therefore certified two questions to the New York Court of Appeals.

2. Summary of the Opinion

By accompanying summary order, the court affirms dismissal of Asinga’s tortious interference with contract, Texas Deceptive Trade Practices Act claim, and intentional infliction of emotional distress claim; the certified issues determine the fate of the remaining tort and products-liability theories.

3. Analysis

3.1 Precedents Cited

A. Framing “economic loss doctrine” under New York law

The opinion’s central move is to treat New York’s “economic loss doctrine” as conceptually unstable and contested. The court relies heavily on the New York Court of Appeals’ recent clarification in IKB Int'l, S.A. v. Wells Fargo Bank, N.A., which states that the “economic loss doctrine” is often a conflation of two different principles: (1) a products-liability “economic loss rule,” and (2) the bar on duplicative tort claims that are essentially contractual.

• IKB Int'l, S.A. v. Wells Fargo Bank, N.A.: Used to narrow the “economic loss rule” to the products-liability context and to separate it from the “duplicative tort” doctrine; also provides the framework (“nature of the injury, how the injury occurred and the harm it caused”) for assessing duplication.
• La Barre v. Mitchell and Schiavone Constr. Co. v. Elgood Mayo Corp.: Invoked for the proposition that, in some formulations, “whether pleaded in negligence or in strict liability,” tort recovery may be barred where a product “does not function properly” and the result is economic loss “other than physical damage to persons or property.” These cases illustrate the pull toward treating “nonperformance/quality” harms as contract-like even when tort labels are used.
• Hemming v. Certainteed Corp. and Amin Realty, LLC v. K & R Const. Corp.: Cited to show that some New York courts articulate the rule broadly, barring even consequential damages arising from defects as nonrecoverable in tort—supporting the Second Circuit’s view that New York’s formulations are inconsistent.
• Washington Apts., L.P. v. Oetiker, Inc., New York Methodist Hosp. v. Carrier Corp., Weiss v. Polymer Plastics Corp., and City of N. Tonawanda v. Penn Power Grp., LLC: Collected to demonstrate that New York courts “rarely define” the doctrine “the same way twice,” reinforcing the uncertainty that motivates certification.

B. Duplicative tort vs. contract—especially when no contract claim exists

The court highlights the second principle identified in IKB Int'l, S.A. v. Wells Fargo Bank, N.A.: tort claims are barred when they are “essentially contractual in nature.” It cites 5th Ave. Chocolatiere, Ltd. v. 540 Acquisition Co. and Hydro Invs., Inc. v. Trafalgar Power Inc. to emphasize the policy rationale: preventing tort remedies from circumventing the limitations of commercial bargains.

• 5th Ave. Chocolatiere, Ltd. v. 540 Acquisition Co.: Supplies the formulation that “essentially contractual” claims do not sound in tort.
• Hydro Invs., Inc. v. Trafalgar Power Inc.: Frames the doctrine’s historical purpose as preventing tort law from erasing negotiated contract limits in the sale-of-goods setting.
• Amin Realty, LLC v. K & R Const. Corp. and County of Suffolk. v. Long Island Lighting: Used to show that courts have sometimes treated losses as “contractual in nature” even when contract claims fail on other grounds—supporting the need to ask whether duplication can bar tort when contract is unavailable.

This strand is pivotal because Asinga “falls between stools”: he lacks a viable contract “bargain” and his consumer-protection claim fails because the gummies were a gift. The opinion recognizes that IKB Int'l, S.A. v. Wells Fargo Bank, N.A. speaks in terms of enforcing a “bargain,” making it unclear how New York would apply “duplication” analysis in a no-contract-remedy posture.

C. What counts as “injury” when the harm is eligibility/discipline rather than impairment

To decide whether losses are “purely economic,” New York tort analysis often looks for injury to “person or property.” The opinion uses 532 Madison Ave. Gourmet Foods, Inc. v. Finlandia Ctr., Inc. to mark the general economic-vs.-personal/property distinction. It then confronts the novelty: Asinga alleges a change in “body chemistry” that does not impair performance but triggers ineligibility to compete.

• Greco v. Nat'l Transp. Co.: Cited for the baseline proposition that an injury to person or property is a necessary component for negligence/strict liability.
• In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig. (No. II) and Harris v. Pfizer Inc.: Used as examples of contamination/exposure cases where courts dismissed claims because allegations amounted to economic loss or speculative “future possibility,” illustrating why “trace chemical presence” alone may not be enough.

D. Duty and reliance in drug-testing and certification contexts

The strongest New York analog the opinion identifies is Landon v. Kroll Lab'y Specialists, Inc., where the Court of Appeals recognized a duty owed by a drug-testing lab to the test subject due to “profound, potentially life-altering” consequences of false positives. The Second Circuit uses Landon v. Kroll Lab'y Specialists, Inc. as a policy-inflected comparator: Asinga similarly alleges life-altering consequences from an adverse test result, and the absence of an alternative statutory remedy can matter.

For reliance-based duty, the opinion cites classic “special relationship” cases:

• Glanzer v. Shepard: Supports the idea that providing a certification or assurance intended to induce reliance may create a duty to the relying party.
• Credit All. Corp. v. Arthur Andersen & Co.: Cited for the principle that an affirmative assumption of a duty of care to a specific party for a specific purpose can exist even without a contract, potentially enabling negligent misrepresentation recovery.

But the opinion also identifies a limiting distinction: Gatorade is not itself a drug-testing lab. That factual difference raises a “best position to prevent” question—central in Landon v. Kroll Lab'y Specialists, Inc.—about where New York would place risk-control responsibility in the chain from manufacturing, labeling, and distribution to the athlete’s anti-doping exposure.

E. The “Horn” litigation as a non-predictive comparator

Both sides invoked the multi-court Horn v. Med. Marijuana, Inc. saga (including Med. Marijuana, Inc. v. Horn and the district court decision) because it also involved unwitting ingestion leading to adverse drug-test consequences and job loss. The Second Circuit explains why it does not resolve the New York question here:

• The district court’s economic-loss dismissal in Horn v. Med. Marijuana, Inc. depended on the same inconsistent New York formulations the Second Circuit finds unclear.
• The Second Circuit and Supreme Court decisions address RICO standing—drawing on Agency Holding Corp. v. Malley-Duff & Assocs., Inc.—not New York tort injury requirements; thus “economic injury” under RICO does not predict “cognizable injury” under New York negligence/strict liability/misrepresentation doctrines.

F. Certification standards

The opinion’s certification analysis is anchored in Second Circuit standards:

• Beck v. Manhattan Coll. and Ortiz v. Ciox Health LLC: Provide the threshold for certifying unsettled state-law issues when prediction is not reliable.
• Nitkewicz v. Lincoln Life & Ann. Co. of N.Y.: Supplies the three-factor test (authoritative state decisions; importance to state policy; whether certification resolves the appeal).
• Barenboim v. Starbucks Corp.: Used for the “predict with confidence” framing.
• Doe v. Guthrie Clinic, Ltd., E. Fork Funding LLC v. U.S. Bank, Nat'l Ass'n, and Georgitsi Realty, LLC v. Penn-Star Ins. Co.: Reinforce that certification is appropriate when the unresolved state-law issue is dispositive of the remaining claims.

3.2 Legal Reasoning

The court’s reasoning proceeds in three steps:

1. Identify doctrinal ambiguity. New York’s “economic loss doctrine” is described as inconsistently defined and, per IKB Int'l, S.A. v. Wells Fargo Bank, N.A., actually a conflation of two principles with different scopes. That ambiguity matters because Asinga’s alleged harms are not a clean “product damaged itself” case and not a clean “contract bargain” case.
2. Recognize the novelty of the alleged injury. The asserted injury is neither classic personal injury (performance impairment, physical symptoms) nor merely disappointed product expectations; it is “eligibility” harm that arises from an internal chemical state detectable through anti-doping testing and enforceable sporting rules.
3. Apply certification criteria. Because there is no authoritative New York Court of Appeals decision on these precise questions, because the questions implicate New York policy (including participation in athletics and defining business liability), and because answers will resolve the appeal, certification is warranted.

Notably, the court does not hold that Asinga has or lacks a cognizable tort injury; it holds that the New York Court of Appeals should define the boundary.

3.3 Impact

The certified questions are poised to shape New York tort law at two sensitive boundaries.

• “No contract remedy” duplication bar. If New York answers “yes” to Question (1), defendants may invoke “duplication” to defeat tort claims even where plaintiffs cannot plead contract/products liability—potentially leaving some reliance-based injuries without remedy. If “no,” New York would preserve tort pathways where contractual allocation is absent, especially for gratuitous distribution, promotional events, or non-purchaser reliance scenarios.
• Eligibility-based injury in sport and regulated testing contexts. If Question (2) is answered “yes,” New York would recognize that nonconsensual ingestion that triggers ineligibility can be a cognizable tort injury—potentially extending beyond athletics to employment/licensing settings where testing regimes convert internal chemistry into legal status (e.g., professional certifications, safety-sensitive jobs). If “no,” New York would likely confine tort recovery to traditional physical impairment/property damage, channeling “status/eligibility” harms toward contract, consumer-protection statutes, or other tailored regimes.
• Labeling/certification reliance. The facts—allegedly unauthorized “NSF Certified for Sport” labeling—invite New York to clarify when a certification mark and its intended reliance creates a “special relationship” duty under negligent misrepresentation principles (as suggested by Glanzer v. Shepard and Credit All. Corp. v. Arthur Andersen & Co.).

Practically, the decision will influence risk management for companies marketing supplements/functional foods to athletes in New York, including audit trails for third-party certifications, lot/batch testing protocols, and representations made at invitational events.

4. Complex Concepts Simplified

• Economic loss rule vs. “economic loss doctrine.” The opinion stresses (via IKB Int'l, S.A. v. Wells Fargo Bank, N.A.) that New York often mixes: (a) a products-liability rule limiting tort recovery for purely economic losses (like replacement costs or disappointed expectations), and (b) a duplication rule barring tort claims that merely restate contract duties.
• “Cognizable injury.” This means a type of harm the law recognizes as sufficient to support a tort claim. Here, the question is whether “ineligibility to compete” caused by nonconsensual ingestion is a recognized injury even without performance impairment or symptoms.
• Negligent misrepresentation and “special relationship.” Ordinarily, negligence does not compensate purely financial loss absent special circumstances. A “special relationship” (e.g., where a defendant provides information/certification to induce reliance by a known group) can create a duty supporting economic damages—an idea drawn from Glanzer v. Shepard and Credit All. Corp. v. Arthur Andersen & Co..
• Certification to the New York Court of Appeals. Certification is not a merits ruling. The federal appellate court asks New York’s highest court to answer state-law questions, then applies those answers to decide the case.

5. Conclusion

Asinga v. Gatorade Co. does not resolve whether Asinga can recover in tort for losses tied to an adverse anti-doping outcome; it spotlights that New York law has not clearly classified (i) the reach of “economic loss” limits when contract/products-liability claims are unavailable and (ii) whether nonconsensual ingestion that triggers eligibility consequences constitutes a cognizable tort injury. By certifying these questions, the Second Circuit positions the New York Court of Appeals to define how modern testing regimes, third-party certifications, and status-based disqualifications fit within traditional tort categories of “economic” versus “personal/property” harm—an answer likely to reverberate beyond sport into other regulated contexts where internal chemistry determines legal and professional standing.